Play all audios:
Access through your institution Buy or subscribe Data from a phase III trial in patients with resected pancreatic ductal adenocarcinoma (PDAC), who generally have a poor prognosis, indicate
that patients receiving adjuvant capecitabine plus gemcitabine have a superior median overall survival duration compared with patients receiving gemcitabine alone (28.0 months versus 25.5
months). Patients received a total of six 4-week treatment cycles, commencing within 12 weeks of tumour resection, following a full recovery from surgery. No significant differences in
self-reported quality of life between the two groups were detected using questionaires at 3, 6 and 12 months into the follow-up period. These data suggest that, despite a higher risk of
adverse events in the capecitabine plus gemcitabine arm, this approach is generally tolerated by patients. These findings provide a new standard-of-care treatment for patients with PDAC
following tumour resection. This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Access Nature and 54 other Nature Portfolio
journals Get Nature+, our best-value online-access subscription $29.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 12 print issues and online access $209.00 per
year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated
during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Neoptolemos J. P. _ et al_. Comparison
of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. _Lancet_
http://dx.doi.org/10.1016/S0140-6736(16)32409-6 (2017) Download references Authors * Peter Sidaway View author publications You can also search for this author inPubMed Google Scholar RIGHTS
AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Sidaway, P. Addition of capecitabine prolongs overall survival. _Nat Rev Clin Oncol_ 14, 198 (2017).
https://doi.org/10.1038/nrclinonc.2017.21 Download citation * Published: 14 February 2017 * Issue Date: April 2017 * DOI: https://doi.org/10.1038/nrclinonc.2017.21 SHARE THIS ARTICLE Anyone
you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the
Springer Nature SharedIt content-sharing initiative